Physician profile
Shane Cox
NPI 1780264226
$4,080.05
in general payments reported to CMS, 2019-2025
34 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 95% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $378 · 2022: $188 · 2023: $464 · 2024: $873 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,430 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,430.29 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $460.19 | 2024-2025 | Tremfya |
| Ardelyx, INC. | $368.58 | 2024-2025 | Ibsrela |
| Abbvie INC. | $351.85 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $276.92 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $253.38 | 2021-2024 | |
| Madrigal Pharmaceuticals | $232.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $223.74 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $207.13 | 2024-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.69 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $142.87 | 2024-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $134.71 | 2024-2025 | Zenpep |
| Pfizer INC. | $108.95 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $107.75 | 2021-2022 | |
| Impulse Dynamics (USA) INC. | $105.77 | 2023 | Optimizer |
| Ipsen Biopharmaceuticals, INC | $103.40 | 2025 | Iqirvo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $98.08 | 2021-2023 | Farxiga |
| Genzyme Corporation | $89.31 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.10 | 2023-2024 | Lifevest |
| Philips North America LLC | $79.06 | 2023-2024 | (Cm9) Amb Mon & Diag Und |
| Bayer Healthcare Pharmaceuticals INC. | $61.82 | 2023-2024 | |
| Gilead Sciences, INC. | $53.81 | 2024-2025 | |
| Evoke Pharma, INC. | $44.13 | 2024 | |
| Ironwood Pharmaceuticals, INC | $38.67 | 2024-2025 | |
| Silk Road Medical, INC. | $33.62 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Vifor Pharma, INC. | $31.10 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $30.22 | 2023 | Exparel |
| Electromed, INC. | $28.35 | 2025 | Smartvest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.34 | 2023-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $26.38 | 2023 | Camzyos |
| Esperion Therapeutics, INC. | $26.06 | 2021-2022 | |
| Novo Nordisk INC | $21.53 | 2025 | Wegovy |
| Cvrx, INC. | $21.31 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.93 | 2023 | Arcalyst |
| Angiodynamics, INC. | $15.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.